Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct rapid diagnosis of rifampicin-resistant M. tuberculosis infection in clinical samples by line probe assay (INNO LiPA Rif-TB).

The new microbiologica - 1 Jul 2004

Cirillo D M, Piana F, Frisicale L, Quaranta M, Riccabone A, Penati V, Vaccarino P, Marchiaro G

Abstract excerpt

M. tuberculosis is one of the leading causes of death worldwide and Multi Drug Resistant Tuberculosis (MDR-TB) is associated with a high case-fatality rate. Rapid identification of resistant strains is crucial to institute prompt appropriate therapy, and prevent the development of further resistance and spreading of MDR strains. The INNO-LiPA Rif. TB is a commercial reverse hybridisation line probe assay designed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antitubercular
Share to Ascitic Fluid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bronchoalveolar Lavage Fluid

Share to Cerebrospinal Fluid

Share to Ethambutol

Share to Pleural Effusion

Share to Streptomycin

Source

Identifiers

PMID: 15460524

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct rapid diagnosis of rifampicin-resistant M. tuberculosis infection in clinical samples by line probe assay (INNO LiPA Rif-TB).PMID 15460524Read ↗

Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Direct detection of multidrug-resistant Mycobacterium tuberculosis in clinical specimens in low- and high-incidence countries by line probe assay.Semantic proximity Read ↗

Rapid detection of mutations in rpoB gene of rifampicin resistant Mycobacterium tuberculosis strains by line probe assay.Semantic proximity Read ↗

Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.Semantic proximity Read ↗

Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policySemantic proximity Read ↗

Molecular identification and characterization of rifampicin-resistant Mycobacterium tuberculosis isolates by line probe assay: an approach for rapid diagnosis of multidrug-resistant tuberculosis.Semantic proximity Read ↗

Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampinSemantic proximity Read ↗

[Direct detection of rifampicin resistant Mycobacterium tuberculosis in sputum by line probe assay (LiPA)].Semantic proximity Read ↗

Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay.Semantic proximity Read ↗

Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam.Semantic proximity Read ↗

Direct Detection of <i>Mycobacterium tuberculosis</i> Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe AssaySemantic proximity Read ↗

[Clinical evaluation of a line probe assay kit for the identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.